Advertisement

The importance of consensus statements on the prevention and treatment of cancer-associated thrombosis

Published:March 28, 2022DOI:https://doi.org/10.1016/j.ejim.2022.03.029
      Venous thromboembolism (VTE) is a common complication among patients with cancer. The 6-month risk of VTE complication for cancer patients is 12-fold higher and as much as 23-fold higher in those receiving chemotherapy or targeted therapy when compared to patients without cancer [
      • Mulder F.I.
      • Horvath-Puho E.
      • van Es N.
      • van Laarhoven H.W.M.
      • Pedersen L.
      • Moik F.
      • Ay C.
      • Buller H.R.
      • Sorensen H.T.
      Venous thromboembolism in cancer patients: a population-based cohort study.
      ]. Furthermore, the 12-month cumulative incidence for VTE has increased three-fold over the past two decades in this patient population [
      • Mulder F.I.
      • Horvath-Puho E.
      • van Es N.
      • van Laarhoven H.W.M.
      • Pedersen L.
      • Moik F.
      • Ay C.
      • Buller H.R.
      • Sorensen H.T.
      Venous thromboembolism in cancer patients: a population-based cohort study.
      ]. Hence, cancer-associated thrombosis (CAT) is a frequent complication that most clinicians caring for patients with cancer must routinely manage.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mulder F.I.
        • Horvath-Puho E.
        • van Es N.
        • van Laarhoven H.W.M.
        • Pedersen L.
        • Moik F.
        • Ay C.
        • Buller H.R.
        • Sorensen H.T.
        Venous thromboembolism in cancer patients: a population-based cohort study.
        Blood. 2021; 137: 1959-1969
        • Khorana A.A.
        • Francis C.W.
        • Culakova E.
        • Kuderer N.M.
        • Lyman G.H.
        Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.
        J Thromb Haemost. 2007; 5: 632-634
        • Lloyd A.J.
        • Dewilde S.
        • Noble S.
        • Reimer E.
        • Lee A.Y.Y.
        What impact does venous thromboembolism and bleeding have on cancer patients' quality of life?.
        Value Health. 2018; 21: 449-455
        • Font C.
        • Nelson A.
        • Garcia-Fernandez T.
        • Prout H.
        • Gee P.
        • Patients' N.S.
        Experience of living with cancer-associated thrombosis in spain (PELICANOS).
        Support Care Cancer. 2018; 26: 3233-3239
        • Noble S.
        • Prout H.
        • Nelson A.
        Patients' experiences of living with cancer-associated thrombosis: the PELICAN study.
        Patient Prefer Adherence. 2015; 9: 337-345
        • Noble S.
        • Nelson A.
        • Scott J.
        • Berger A.
        • Schmidt K.
        • Swarnkar P.
        • Lee A.
        Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA).
        Res Pract Thromb Haemost. 2020; 4: 154-160
        • Prandoni P.
        • Lensing A.W.
        • Piccioli A.
        • Bernardi E.
        • Simioni P.
        • Girolami B.
        • Marchiori A.
        • Sabbion P.
        • Prins M.H.
        • Noventa F.
        • Girolami A.
        Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
        Blood. 2002; 100: 3484-3488
        • Sorensen H.T.
        • Mellemkjaer L.
        • Olsen J.H.
        • Baron J.A.
        Prognosis of cancers associated with venous thromboembolism.
        N Engl J Med. 2000; 343: 1846-1850
        • Key N.S.
        • Khorana A.A.
        • Kuderer N.M.
        • Bohlke K.
        • Lee A.Y.Y.
        • Arcelus J.I.
        • Wong S.L.
        • Balaban E.P.
        • Flowers C.R.
        • Francis C.W.
        • Gates L.E.
        • Kakkar A.K.
        • Levine M.N.
        • Liebman H.A.
        • Tempero M.A.
        • Lyman G.H.
        • Falanga A.
        Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.
        J Clin Oncol. 2020; 38: 496-520
        • Lyman G.H.
        • Carrier M.
        • Ay C.
        • et al.
        American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
        Blood Adv. 2021; 5: 927-974
        • Munoz M.A.J.
        • Gallardo D.E.
        • Garcia E.I.
        • Macias M.R.
        • Martinez-Marin V.
        • Pachon O.V.
        • Perez S.P.
        • Quintanar V.T.
        • Salgado F.M.
        SEOM clinical guideline of venous thromboembolism (VTE) and cancer.
        Clin Transl Oncol. 2019; 22 (2020): 171-186
        • Jimenez-Fonseca P.
        • Gallardo E.
        • Arranz A.F.
        • Blanco J.M.
        • Callejo A.
        • Lavin D.C.
        • Costa R.M.
        • Mosquera J.
        • Rodrigo A.
        • Sanchez M.R.
        • Vares G.M.
        • Munoz A.
        • Carmona-Bayonas A.
        Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
        Eur J Intern Med. 2022; 100: 36-48https://doi.org/10.1016/j.ejim.2022.02.020
        • Alonso-Coello P.
        • Oxman A.D.
        • Moberg J.
        • Brignardello-Petersen R.
        • Akl E.A.
        • Davoli M.
        • Treweek S.
        • Mustafa R.A.
        • Vandvik P.O.
        • Meerpohl J.
        • Guyatt G.H.
        • Schunemann H.J.
        • Group G.W.
        GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines.
        BMJ. 2016; 353: i2089
        • Alonso-Coello P.
        • Schunemann H.J.
        • Moberg J.
        • Brignardello-Petersen R.
        • Akl E.A.
        • Davoli M.
        • Treweek S.
        • Mustafa R.A.
        • Rada G.
        • Rosenbaum S.
        • Morelli A.
        • Guyatt G.H.
        • Oxman A.D.
        • Group G.W.
        GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction.
        BMJ. 2016; 353: i2016
        • Schunemann H.J.
        • Mustafa R.
        • Brozek J.
        • Santesso N.
        • Alonso-Coello P.
        • Guyatt G.
        • Scholten R.
        • Langendam M.
        • Leeflang M.M.
        • Akl E.A.
        • Singh J.A.
        • Meerpohl J.
        • Hultcrantz M.
        • Bossuyt P.
        • Oxman A.D.
        • Group G.W.
        GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health.
        J Clin Epidemiol. 2016; 76: 89-98

      Linked Article